XTX Topco Ltd Lowers Stake in Edwards Lifesciences Co. (NYSE:EW)

XTX Topco Ltd lowered its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 60.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,900 shares of the medical research company's stock after selling 32,396 shares during the period. XTX Topco Ltd's holdings in Edwards Lifesciences were worth $1,547,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $26,000. Millstone Evans Group LLC bought a new stake in Edwards Lifesciences in the 4th quarter worth approximately $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $30,000. Roble Belko & Company Inc bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at $46,000. Finally, Catalyst Capital Advisors LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth $54,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Wolfe Research downgraded Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Truist Financial dropped their price objective on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Barclays upped their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Evercore ISI dropped their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research note on Wednesday, February 12th. Finally, Canaccord Genuity Group boosted their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of "Hold" and a consensus target price of $78.55.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of the business's stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $69.81, for a total transaction of $663,195.00. Following the transaction, the vice president now owns 47,206 shares of the company's stock, valued at approximately $3,295,450.86. The trade was a 16.75 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares of the company's stock, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,853 shares of company stock worth $5,163,062 in the last three months. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded up $0.36 during midday trading on Friday, reaching $71.56. 3,235,636 shares of the stock traded hands, compared to its average volume of 4,931,213. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The stock's fifty day moving average is $71.31 and its 200-day moving average is $70.92. The stock has a market cap of $42.07 billion, a P/E ratio of 10.27, a PEG ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.